TheraRadar
Clinical-Stage Companies / Dynavax Technologies Corporation

Dynavax Technologies Corporation

Pre-Approval PRO BETA
16
Total Trials
4
Phase 3
5
Phase 2
2
Recruiting
135
Score

Pipeline by Phase

Phase 3
4
Phase 2
5
Phase 1
10

Therapeutic Focus

Vaccine-Preventable Diseases Healthy Shingles Herpes Zoster Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

Clinical Trials (16)

NCT00985426 Phase 3 COMPLETED

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Started: 9/1/2009

NCT02117934 Phase 3 COMPLETED

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Started: 4/1/2014

NCT01195246 Phase 3 COMPLETED

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

Started: 12/1/2010

NCT01005407 Phase 3 COMPLETED

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

Started: 2/1/2010

NCT07207408 Phase 2 RECRUITING

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

Started: 9/11/2025

NCT05506969 Phase 2 COMPLETED

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Started: 8/9/2022

NCT06569823 Phase 1 RECRUITING

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

Started: 6/17/2024

NCT03934736 Phase 1 COMPLETED

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Started: 4/22/2019

NCT05245838 Phase 1 COMPLETED

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Started: 1/10/2022

NCT02521870 Phase 1 TERMINATED

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Started: 9/1/2015

NCT02266147 Phase 1 TERMINATED

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Started: 10/1/2014

NCT03326752 Phase 1 COMPLETED

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Started: 9/20/2017

NCT01023230 Phase 1 COMPLETED

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

Started: 9/1/2009

NCT00599001 Phase 1 COMPLETED

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Started: 1/1/2008

NCT00823862 Phase 1 COMPLETED

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Started: 10/1/2008

NCT01999699 Phase 1 COMPLETED

A Study of the Immune Response to Heplisav in Healthy Older Adults

Started: 11/1/2013

Drug Candidates

Z-1018 Shingrix rF1V-1018 rF1V vaccine HEPLISAV-B® SD-101(1) Pembrolizumab SD-101(2) SD-101(3) HEPLISAV-B
Activity Status: Active
Last Trial Started: 9/11/2025
Last Trial Ended: 4/26/2024
Trials (12 months): 1
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.